Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study

Simple item page
dc.conference.dateMAR 02-04, 2020
dc.conference.titleEuropean-Society-for-Medical-Oncology (ESMO) Targeted Anticancer Therapies Congress (TAT)
dc.contributor.authorAngevin, E.
dc.contributor.authorGroenland, S.
dc.contributor.authorBauer, T.
dc.contributor.authorRischin, D.
dc.contributor.authorGardeazabal, I.
dc.contributor.authorMoreno, V.
dc.contributor.authorTrigo, J. M.
dc.contributor.authorChisamore, M.
dc.contributor.authorShaik, J.
dc.contributor.authorRigat, F.
dc.contributor.authorEllis, C.
dc.contributor.authorChen, H.
dc.contributor.authorGagnon, R.
dc.contributor.authorScherer, S. J.
dc.contributor.authorTurner, D.
dc.contributor.authorYadavilli, S.
dc.contributor.authorBallas, M.
dc.contributor.authorHoos, A.
dc.contributor.authorMaio, M.
dc.contributor.authoraffiliation[Angevin, E.] Gustave Roussy Inst Cancerol, Villejuif, France
dc.contributor.authoraffiliation[Groenland, S.] Netherlands Canc Inst, Antoni van Leeuwenhoek, Amsterdam, Netherlands
dc.contributor.authoraffiliation[Bauer, T.] Sarah Cannon Res Inst Tennessee Oncol PLLC, Nashville, TN USA
dc.contributor.authoraffiliation[Rischin, D.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
dc.contributor.authoraffiliation[Rischin, D.] Univ Melbourne, Melbourne, Vic, Australia
dc.contributor.authoraffiliation[Gardeazabal, I.] Hosp Univ Marques Valdecilla, Santander, Spain
dc.contributor.authoraffiliation[Moreno, V.] Univ Hosp Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain
dc.contributor.authoraffiliation[Trigo, J. M.] Hosp Univ Virgen de la Victoria, Malaga, Spain
dc.contributor.authoraffiliation[Chisamore, M.] Merck & Co Inc, N Wales, PA USA
dc.contributor.authoraffiliation[Shaik, J.] GSK, Collegeville, PA USA
dc.contributor.authoraffiliation[Ellis, C.] GSK, Collegeville, PA USA
dc.contributor.authoraffiliation[Chen, H.] GSK, Collegeville, PA USA
dc.contributor.authoraffiliation[Gagnon, R.] GSK, Collegeville, PA USA
dc.contributor.authoraffiliation[Scherer, S. J.] GSK, Collegeville, PA USA
dc.contributor.authoraffiliation[Turner, D.] GSK, Collegeville, PA USA
dc.contributor.authoraffiliation[Yadavilli, S.] GSK, Collegeville, PA USA
dc.contributor.authoraffiliation[Ballas, M.] GSK, Collegeville, PA USA
dc.contributor.authoraffiliation[Hoos, A.] GSK, Collegeville, PA USA
dc.contributor.authoraffiliation[Rigat, F.] GSK, Stevenage, Herts, England
dc.contributor.authoraffiliation[Maio, M.] GSK, Stevenage, Herts, England
dc.contributor.authoraffiliation[Maio, M.] Univ Hosp Siena, Siena, Italy
dc.contributor.funderGlaxoSmithKline (GSK)
dc.contributor.funderMerck Sharp Dohme Corp.
dc.date.accessioned2025-01-07T15:03:58Z
dc.date.available2025-01-07T15:03:58Z
dc.date.issued2020-03-01
dc.identifier.doi10.1016/j.annonc.2020.01.059
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420359925/pdf
dc.identifier.urihttps://hdl.handle.net/10668/26852
dc.identifier.wosID521074400007
dc.issue.number1
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.page.numberS3-S3
dc.publisherOxford univ press
dc.rights.accessRightsopen access
dc.titlePharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen de la Victoria

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía